foxo4 dri peptide senolytic human trial FOXO4-DRI UK | Research The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Buy FOXO4 DRI Peptide Vial UK PharmaLabGlobal Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging
Pay in 4 interest-free payments of $6.48 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



